Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · IEX Real-Time Price · USD
109.01
+0.17 (0.16%)
At close: Jul 19, 2024, 4:00 PM
109.06
+0.05 (0.05%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,800 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
2,800
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,372,634
Profits / Employee
$118,141
Market Cap
6.87B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,800 | 0 | - |
Dec 31, 2022 | 2,800 | -400 | -12.50% |
Dec 31, 2021 | 3,200 | 1,260 | 64.95% |
Dec 31, 2020 | 1,940 | 320 | 19.75% |
Dec 31, 2019 | 1,620 | 260 | 19.12% |
Dec 31, 2018 | 1,360 | 150 | 12.40% |
Dec 31, 2017 | 1,210 | 170 | 16.35% |
Dec 31, 2016 | 1,040 | 130 | 14.29% |
Dec 31, 2015 | 910 | 40 | 4.60% |
Dec 31, 2014 | 870 | 60 | 7.41% |
Dec 31, 2013 | 810 | 200 | 32.79% |
Dec 31, 2012 | 610 | 179 | 41.53% |
Dec 31, 2011 | 431 | 189 | 78.10% |
Dec 31, 2010 | 242 | 14 | 6.14% |
Dec 31, 2009 | 228 | 12 | 5.56% |
Dec 31, 2008 | 216 | -193 | -47.19% |
Dec 31, 2007 | 409 | 224 | 121.08% |
Dec 31, 2007 | 185 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Grifols | 23,737 |
Penumbra | 4,200 |
HealthEquity | 3,150 |
Tempus AI | 1,952 |
Repligen | 1,783 |
Exelixis | 1,310 |
Ionis Pharmaceuticals | 927 |
Blueprint Medicines | 655 |
JAZZ News
- 4 days ago - Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024 - PRNewsWire
- 13 days ago - Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer - PRNewsWire
- 4 weeks ago - Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday? - Benzinga
- 4 weeks ago - Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study - Reuters
- 4 weeks ago - Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor - PRNewsWire
- 7 weeks ago - Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 - PRNewsWire
- 7 weeks ago - Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 - PRNewsWire
- 7 weeks ago - Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences - PRNewsWire